Global Avascular Necrosis Market

Avascular Necrosis Market Size Summary, Size & Emerging Trends

According to Decisions Advisors, The Global Avascular Necrosis Market Size is expected to Grow from USD 1.8 Billion in 2024 to USD 3.9 Billion by 2035, at a CAGR of 7.3% during the forecast period 2025-2035. Increasing prevalence of orthopedic disorders, aging population, and rising awareness about early diagnosis and treatment are key factors propelling market growth.

Key Market Insights

• North America is projected to hold the largest market share in the avascular necrosis market during the forecast period.
• In terms of disease type, trauma-related avascular necrosis dominated the market share in 2024 due to high incidence caused by fractures and injuries.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 1.8 Billion
• 2035 Projected Market Size: USD 3.9 Billion
• CAGR (2025-2035): 7.3%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Avascular Necrosis Market

The avascular necrosis market centers on diagnosing and treating the death of bone tissue caused by a disrupted blood supply, which results in joint pain and limited mobility. This condition mainly impacts joints such as the hips, knees, and shoulders. Treatment approaches include drug therapy, surgical procedures, and regenerative therapies aimed at restoring joint function and reducing symptoms. Recent advances in diagnostic imaging, like MRI and CT scans, along with minimally invasive surgical techniques, are enhancing early detection and improving treatment outcomes. The market growth is driven by increasing healthcare spending, a rising number of bone injuries, and a growing demand for effective treatment options worldwide. Additionally, government programs promoting orthopedic health awareness play a significant role in encouraging early diagnosis and wider acceptance of treatments. These factors combined are fueling innovation and expansion in the avascular necrosis market globally.

Avascular Necrosis Market Trends

• Growing use of MRI and advanced imaging techniques for early diagnosis.
• Increasing adoption of minimally invasive surgical procedures.
• Rising investments in orthopedic research and development.

Avascular Necrosis Market Dynamics

Driving Factors:

The avascular necrosis market is primarily driven by the increasing prevalence of traumatic injuries

The avascular necrosis market is primarily driven by the increasing prevalence of traumatic injuries and chronic diseases like osteoporosis and sickle cell anemia, which disrupt blood supply to bones. Additionally, the global rise in aging populations contributes to higher disease incidence. Enhanced healthcare infrastructure and growing awareness among patients facilitate early diagnosis and increased treatment adoption. These combined factors fuel steady market growth. As more patients seek effective solutions, demand for innovative therapies and advanced diagnostic tools rises, supporting ongoing expansion of the avascular necrosis market throughout the forecast period.

Restrain Factors:

Market growth is constrained by the high cost of surgical treatments

Market growth is constrained by the high cost of surgical treatments, which limits affordability, especially in low-income regions. Furthermore, a lack of awareness regarding early symptoms delays diagnosis and treatment initiation. In many developing countries, there is a shortage of skilled orthopedic surgeons and advanced diagnostic facilities, restricting patient access to care. Long-term medication use also presents challenges, as side effects and complications can reduce patient adherence. These factors collectively hinder market penetration and slow growth, necessitating efforts to improve awareness, reduce costs, and enhance healthcare infrastructure for better market expansion.

Opportunity:

Research into regenerative therapies such as stem cell treatments

Research into regenerative therapies such as stem cell treatments and tissue engineering is creating significant growth opportunities in the avascular necrosis market. These cutting-edge therapies offer the potential to restore bone function more effectively than conventional methods. Increasing demand for personalized medicine and advancements in surgical technology also open new revenue streams. Moreover, emerging markets with improving healthcare infrastructure and rising investments present untapped potential for market players. These opportunities encourage innovation and expansion, enabling companies to develop novel treatments and capture growing patient populations in underserved regions.

Challenges:

Delayed diagnosis remains a major challenge

Delayed diagnosis remains a major challenge, as many patients are identified only after the disease has progressed to advanced, less treatable stages. The market also faces competition from alternative and non-surgical therapies, which may be preferred for cost or convenience reasons. Ensuring that advanced treatments are both affordable and accessible is critical for long-term market growth, especially in developing regions. Addressing these challenges requires improving early detection methods, increasing patient and physician awareness, and developing cost-effective treatment options to enhance market penetration and sustainable growth.

Global Avascular Necrosis Market Ecosystem Analysis

The global avascular necrosis market ecosystem comprises orthopedic surgeons, diagnostic centers, pharmaceutical firms, medical device manufacturers, distributors, and regulatory authorities. Collaboration among these stakeholders promotes innovation and ensures adherence to safety and efficacy standards. Ongoing investments in research and clinical trials enhance product development and patient outcomes. Additionally, supportive healthcare policies and reimbursement systems play a crucial role in facilitating market growth. Together, these elements create a robust framework driving the global expansion of the avascular necrosis market.

Global Avascular Necrosis Market, By Disease Type

What factors enabled the trauma-related avascular necrosis segment to dominate the market in 2024?

The trauma-related avascular necrosis segment dominated the market in 2024, accounting for approximately 60% of total revenue share, due to several key factors. First, the rising incidence of traumatic injuries leading to bone damage has significantly increased the demand for targeted treatments in this segment. Additionally, advancements in diagnostic techniques and early intervention strategies have improved patient outcomes, making trauma-related avascular necrosis management more effective and widely adopted. The segment also benefits from strong clinical evidence supporting the efficacy of current treatment protocols, which has boosted physician preference and patient trust. Furthermore, ongoing research and innovation in therapeutic options, including minimally invasive procedures and regenerative therapies, have enhanced the segment’s competitive edge over other types.

Why is there an increasing demand for treatments in the non-trauma-related avascular necrosis segment?

The non-trauma-related avascular necrosis segment held the remaining market share in 2024 and has been growing steadily due to several important factors. Increased awareness and better diagnosis of non-traumatic causes such as prolonged corticosteroid use, alcoholism, and metabolic disorders have led to a rise in identified cases. Advances in early detection methods and more effective treatment options tailored to these specific causes have also contributed to expanding demand. Additionally, ongoing research and development in therapeutic approaches have improved patient outcomes, encouraging more healthcare providers to focus on this segment.

Global Avascular Necrosis Market, By Treatment Type

How did the surgical segment achieve market leadership in avascular necrosis treatment in 2024?

Surgical intervention led the avascular necrosis market in 2024, capturing approximately 55% of total revenue share, primarily due to its effectiveness in advanced-stage cases where non-surgical treatments are less viable. Procedures such as core decompression, osteotomy, bone grafting, and joint replacement have shown reliable outcomes in relieving pain, preserving joint function, and improving quality of life. The growing number of patients presenting with late-stage avascular necrosis where surgery is often the only effective option has further fueled demand. Additionally, technological advancements in surgical techniques, minimally invasive procedures, and post-operative recovery have enhanced patient outcomes and surgeon confidence, making surgical intervention the treatment of choice.

What factors contributed to drug therapy holding approximately 30% of the avascular necrosis market in 2024?

Drug therapy accounted for approximately 30% of the avascular necrosis market, driven by its vital role in early-stage management and symptom control. Medications focused on pain relief and improving blood circulation have been widely adopted as first-line treatments, particularly for patients not yet requiring surgical intervention. The growing awareness of early diagnosis and non-invasive treatment options has fueled the demand for pharmacological solutions. Additionally, ongoing advancements in drug development, including novel agents targeting bone regeneration and vascular health, have expanded the clinical utility of drug therapy.

North America led the global avascular necrosis market in 2024, accounting for nearly 40% of total revenue.

This dominance is attributed to its well-established healthcare infrastructure, advanced diagnostic technologies, and strong presence of key market players. High awareness of orthopedic conditions, greater access to surgical interventions, and favorable reimbursement policies further support market growth in the region. Additionally, increased healthcare spending and a large aging population contribute to higher diagnosis and treatment rates, solidifying North America’s position as the leading regional market.

The United States emerged as the single largest country-level market for avascular necrosis in 2024.

This leadership is supported by a combination of advanced medical infrastructure, high adoption of new technologies, and strong patient demand for early and effective treatment options. A well-regulated healthcare system, ongoing research in orthopedic therapies, and significant investment in regenerative medicine also contribute to the country’s dominance. Furthermore, the U.S. sees a high prevalence of risk factors such as steroid use, alcohol abuse, and trauma injuries, increasing the patient pool for avascular necrosis treatment.

Asia Pacific is the fastest-growing region in the avascular necrosis market,

Driven by rapid urbanization, improving healthcare infrastructure, and increasing healthcare expenditure. Countries like China, India, and South Korea are witnessing a rise in orthopedic conditions due to changing lifestyles, growing aging populations, and higher rates of trauma-related injuries. Government initiatives to improve access to diagnostics and treatments, along with rising patient awareness, are further boosting growth. Moreover, the region's large population base and growing demand for cost-effective therapies make it a key area of opportunity for market expansion.

China and India are experiencing rapid growth in the avascular necrosis market

Due to expanding healthcare access, increasing awareness of orthopedic disorders, and a rising middle-class population. Both countries are investing heavily in healthcare infrastructure and innovation, making advanced diagnostic tools and treatments more widely available. In China, traditional medicine is also being integrated with modern therapies, creating diverse treatment options. India, on the other hand, is seeing growth in medical tourism and public health initiatives, which are improving early diagnosis rates and patient outcomes across the country.

WORLDWIDE TOP KEY PLAYERS IN THE AVASCULAR NECROSIS MARKET INCLUDE

• Zimmer Biomet Holdings, Inc.
• Stryker Corporation
• Johnson & Johnson Services, Inc.
• Smith & Nephew plc
• Medtronic plc
• Globus Medical, Inc.
• Arthrex, Inc.
• CONMED Corporation
• Wright Medical Group N.V.
• Exactech, Inc.
• Others

Product Launches in Avascular Necrosis Market

• In February 2025, Zimmer Biomet Holdings, Inc. launched a next-generation hip implant with improved durability and minimally invasive surgical compatibility in North America, targeting patients requiring joint replacement surgery. This launch strengthens Zimmer Biomet’s position in the orthopedic implant market and meets growing demand for advanced surgical solutions.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the avascular necrosis market based on the below-mentioned segments: 

Global Avascular Necrosis Market, By Disease Type

• Trauma?Related
• Non?Trauma?Related

Global Avascular Necrosis Market, By Treatment Type

• Drug Therapy
• Surgical Intervention
• Regenerative Therapy

Global Avascular Necrosis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa